diplomsko delo
Abstract
Bispecifična monoklonska protitelesa (bsMAb) so beljakovine, ki se lahko vežejo na dve različni mesti za vezavo antigenov v eni molekuli. S hkratnim prepoznavanjem dveh različnih tarč lahko bispecifična protitelesa zavirajo dve signalni poti, tako da so usmerjena na dva različna receptorja na isti celici ali da sočasno usmerjajo dva različna liganda s pomočjo dveh fizično povezanih paratopov. Trenutno sta široko raziskana dva glavna razreda bispecifičnih protiteles: IgG podobna bispecifična monoklonska protitelesa in bispecifična monoklonska protitelesa, ki niso podobna IgG. Protitelesa, podobna IgG, so strukturno enaka naravnim molekulam IgG, vendar jih naravni limfociti B ne morejo sintetizirati. To pomeni, da so raziskave in razvoj teh molekul usmerjene predvsem v razvoj celičnih linij, ki jih lahko sintetizirajo. Bispecifična protitelesa, ki niso podobna IgG, ne vsebujejo dela Fc in so sestavljena iz ene polipeptidne verige - to olajša nadaljnjo obdelavo. Bispecifična protitelesa je težko proizvajati v velikem obsegu. Sinteza teh molekul zahteva obsežno proteinsko inženirstvo in razvoj proizvodnega postopka. Bispecifična protitelesa lahko izboljšajo možnosti zdravljenja raka, avtoimunskih in vnetnih bolezni. Čeprav so se nekatere metode izkazale za zelo uspešne pri sintezi varne in močne molekule, je pomembno poenostaviti strukturo in postopek proizvodnje, da bi se naslednje generacije teh molekul lahko uporabljale v večjem obsegu.
Keywords
biotehnologija;monoklonska protitelesa;bispecifična monoklonska protitelesa;sinteza;bioterapevtiki;
Data
Language: |
Slovenian |
Year of publishing: |
2023 |
Typology: |
2.11 - Undergraduate Thesis |
Organization: |
UL BF - Biotechnical Faculty |
Publisher: |
[M. Matov] |
UDC: |
616-097.3:577.27(043.2) |
COBISS: |
164181763
|
Views: |
10 |
Downloads: |
4 |
Average score: |
0 (0 votes) |
Metadata: |
|
Other data
Secondary language: |
English |
Secondary title: |
Bispecific monoclonal antibodies |
Secondary abstract: |
Bispecific monoclonal antibodies (bsMAb) are proteins capable of binding to two
different antigen-binding sites in one molecule. By simultaneous recognition of two different targets, bispecific antibodies can inhibit two signaling pathways by targeting two different receptors on the same cell or by targeting two different ligands simultaneously using two physically connected paratopes. Currently, two major classes of bispecific antibodies are widely studied: IgG-like bispecific antibodies and non-IgG-like bispecific monoclonal antibodies. IgG-like antibodies are structurally equal to natural IgG molecules; however, they cannot be synthesized by natural B lymphocytes. This means that resources are mainly put into developing cell lines that can synthesize them. Non-IgG-like bispecific antibodies do not contain a Fc-portion and are made up from a single polypeptide chain – this eases upstream and downstream processing. Bispecific antibodies can be difficult to produce in high-scale production. The synthesis of these molecules requires extensive protein-engineering and development of the manufacturing process. Bispecific antibodies might improve treatment options against cancer, autoimmune diseases, and inflammatory diseases. Although some methods have proven great success in synthesizing a safe and powerful molecule, it’s important to simplify the structure and production procedure so next generations of these molecules can be more widely used. |
Secondary keywords: |
biotechnology;monoclonal antibodies;bispecific monoclonal antibodies;synthesis;biotherapeutics; |
Type (COBISS): |
Bachelor thesis/paper |
Study programme: |
0 |
Thesis comment: |
Univ. v Ljubljani, Biotehniška fak., Študij biotehnologije |
Pages: |
1 spletni vir (1 datoteka PDF (VI, 22 str.)) |
ID: |
19917030 |